Key Takeaways
- Shares of Silo Pharma climbed 47.55% during after-hours trading Monday, reaching $0.52
- A Rule 71(3) communication from the European Patent Office indicates plans to approve a patent for the company’s PTSD prevention treatment
- The intellectual property protects methods utilizing serotonin 4 (5-HT4) receptor agonists for preventing stress-related fear and depressive symptoms
- Columbia University exclusively licensed the patent to Silo Pharma, with anticipated coverage throughout key European territories
- The company maintains a market capitalization near $4.98 million, trading significantly under its 52-week peak of $1.18
Silo Pharma experienced a significant boost Monday following the European Patent Office’s (EPO) issuance of a Rule 71(3) communication — an official indicator of patent approval intent — for an innovative preventative approach to PTSD treatment.
The application, designated “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” centers on the serotonin 4 (5-HT4) receptor mechanism. This methodology emphasizes preventing stress-related fear and depressive behaviors proactively, distinguishing itself from conventional post-symptom interventions.
Columbia University granted Silo Pharma exclusive licensing rights to this patent. The company is currently assessing Unitary Patent protection options alongside national validation procedures throughout Europe to maximize territorial reach.
CEO Eric Weisblum characterized the development as a “high-value milestone” that bolsters the organization’s worldwide intellectual property portfolio.
Patent Scope and Applications
The approved claims encompass methodologies for preventing stress-triggered fear responses, depressive-type behaviors, and associated affective conditions through specific 5-HT4 receptor agonists.
This represents a departure from conventional PTSD interventions, which address post-onset symptoms. Silo’s strategy concentrates on establishing stress resilience proactively.
The patent provides direct support for SPC-15, the firm’s primary PTSD development program. Silo’s complete development portfolio encompasses SP-26 for fibromyalgia and chronic pain management, plus early-stage candidates addressing Alzheimer’s disease.
Stock Performance Analysis
SILO concluded Monday’s standard trading session at $0.36 before surging to $0.52 during extended hours — representing a 47.55% increase.
The equity’s 52-week trading range provides broader context: it reached a peak of $1.18 and touched a bottom of $0.22 throughout the past twelve months. That represents substantial volatility for an entity with approximately $5 million in market capitalization.
Benzinga’s equity analysis indicates SILO demonstrated negative price momentum across all timeframes prior to Monday’s announcement.
The after-hours rally propelled the stock above the $0.50 threshold for the first time in recent sessions, though it continues trading well beneath its annual high.
Once officially finalized, the EPO approval is anticipated to provide Silo’s PTSD treatment with protection throughout principal European markets.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
